{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:05:48Z","timestamp":1767139548410,"version":"build-2238731810"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00347-019-00963-z","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T12:33:32Z","timestamp":1567773212000},"page":"467-471","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Vogt-Koyanagi-Harada-artige Uveitis unter Immun-Checkpoint-Inhibitor-Therapie beim metastasierten malignen Melanom","Vogt-Koyanagi-Harada-like uveitis under immune checkpoint inhibitor treatment for metastasized malignant melanoma"],"prefix":"10.1007","volume":"117","author":[{"given":"Nata\u0161a","family":"Mihailovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Dyballa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia","family":"Herz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Fluck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maged","family":"Alnawaiseh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph-Laurent","family":"Mert\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Eter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,5]]},"reference":[{"key":"963_CR1","volume-title":"Ophthalmology","author":"M Yanoff","year":"2008","unstructured":"Yanoff\u00a0M, Duker\u00a0J (2008) Ophthalmology, 3.\u00a0Aufl. Mosby, St. Louis","edition":"3"},{"key":"963_CR2","volume-title":"Clinical ophthalmology: a systematic approach","author":"J Kanski","year":"2011","unstructured":"Kanski\u00a0J, Bowling\u00a0B (2011) Clinical ophthalmology: a systematic approach, 7.\u00a0Aufl. Elsevier Saunders, New York","edition":"7"},{"key":"963_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13023-016-0412-4","volume":"11","author":"MM Lavezzo","year":"2016","unstructured":"Lavezzo\u00a0MM, Sakata\u00a0VM, Morita\u00a0C, Rodriguez\u00a0EE, Abdallah\u00a0SF, da Silva\u00a0FT, Hirata\u00a0CE, Yamamoto\u00a0JH (2016) Vogt-Koyanagi-Harada disease: review of a\u00a0rare autoimmune disease targeting antigens of melanocytes. Orphanet J Rare Dis 11:29. \nhttps:\/\/doi.org\/10.1186\/s13023-016-0412-4","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"963_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.12766","volume":"290","author":"BA Wilky","year":"2019","unstructured":"Wilky\u00a0BA (2019) Immune checkpoint inhibitors: the linchpins of modern immunotherapy. Immunol Rev 290(1):6\u201323. \nhttps:\/\/doi.org\/10.1111\/imr.12766","journal-title":"Immunol Rev"},{"key":"963_CR5","unstructured":"https:\/\/www.aerzteblatt.de\/nachrichten\/70856\/Melanom-Adjuvantes-Ipilimumab-erhoeht-Ueberlebenschancen\n\n. Zugegriffen: 5. Aug. 2019"},{"key":"963_CR6","unstructured":"https:\/\/www.springermedizin.de\/eu-zulassung-fuer-nivolumab\/16124992\n\n. Zugegriffen: 5. Aug. 2019"},{"key":"963_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02373-1","author":"M Friedrich","year":"2019","unstructured":"Friedrich\u00a0M, Jasinski-Bergner\u00a0S, Lazaridou\u00a0MF, Subbarayan\u00a0K, Massa\u00a0C, Tretbar\u00a0S, Mueller\u00a0A, Handke\u00a0D, Biehl\u00a0K, Bukur\u00a0J, Donia\u00a0M, Mandelboim\u00a0O, Seliger\u00a0B (2019) Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy. Cancer Immunol Immunother. \nhttps:\/\/doi.org\/10.1007\/s00262-019-02373-1","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"963_CR8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3238\/arztebl.2019.0119","volume":"116","author":"L Heinzerling","year":"2019","unstructured":"Heinzerling\u00a0L, de Toni\u00a0EN, Schett\u00a0G, Hundorfean\u00a0G, Zimmer\u00a0L (2019) Checkpoint inhibitors. Dtsch Arztebl Int 116(8):119\u2013126. \nhttps:\/\/doi.org\/10.3238\/arztebl.2019.0119","journal-title":"Dtsch Arztebl Int"},{"issue":"6","key":"963_CR9","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","volume":"38","author":"LA Dalvin","year":"2018","unstructured":"Dalvin\u00a0LA, Shields\u00a0CL, Orloff\u00a0M, Sato\u00a0T, Shields\u00a0JA (2018) Checkpoint inhibitors immune therapy: systemic indications and ophthalmic side effects. Retina 38(6):1063\u20131078. \nhttps:\/\/doi.org\/10.1097\/IAE.0000000000002181","journal-title":"Retina"},{"issue":"11","key":"963_CR10","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3928\/23258160-20171030-09","volume":"48","author":"MT Witmer","year":"2017","unstructured":"Witmer\u00a0MT (2017) Treatment of Ipilimumab-induced Vogt-Koyanagi-Harada syndrome with oral dexamethasone. Ophthalmic Surg Lasers Imaging Retina 48(11):928\u2013931. \nhttps:\/\/doi.org\/10.3928\/23258160-20171030-09","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"2","key":"963_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/CJI.0000000000000066","volume":"38","author":"JN Crosson","year":"2015","unstructured":"Crosson\u00a0JN, Laird\u00a0PW, Debiec\u00a0M, Bergstrom\u00a0CS, Lawson\u00a0DH, Yeh\u00a0S (2015) Vogt-Koyanagi-Harada-like syndrome after CTLA\u20114 inhibition with ipilimumab for metastatic melanoma. J\u00a0Immunother 38(2):80\u201384. \nhttps:\/\/doi.org\/10.1097\/CJI.0000000000000066","journal-title":"J Immunother"},{"issue":"4","key":"963_CR12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/ICB.0b013e31824f7130","volume":"6","author":"RK Wong","year":"2012","unstructured":"Wong\u00a0RK, Lee\u00a0JK, Huang\u00a0JJ (2012) Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of vogt-koyanagi-harada syndrome. Retin Cases Brief Rep 6(4):423\u2013426. \nhttps:\/\/doi.org\/10.1097\/ICB.0b013e31824f7130","journal-title":"Retin Cases Brief Rep"},{"issue":"1","key":"963_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000496682","volume":"10","author":"S Obata","year":"2019","unstructured":"Obata\u00a0S, Saishin\u00a0Y, Teramura\u00a0K, Ohji\u00a0M (2019) Vogt-Koyanagi-Harada disease-like uveitis during nivolumab (anti-PD\u20111 antibody) treatment for metastatic cutaneous malignant melanoma. Case Rep Ophthalmol 10(1):67\u201374. \nhttps:\/\/doi.org\/10.1159\/000496682","journal-title":"Case Rep Ophthalmol"},{"issue":"6","key":"963_CR14","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/1346-8138.14273","volume":"45","author":"T Fujimura","year":"2018","unstructured":"Fujimura\u00a0T, Kambayashi\u00a0Y, Tanita\u00a0K, Sato\u00a0Y, Hidaka\u00a0T, Otsuka\u00a0A, Tanaka\u00a0H, Furudate\u00a0S, Hashimoto\u00a0A, Aiba\u00a0S (2018) HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib\/trametinib therapy. J\u00a0Dermatol 45(6):735\u2013737. \nhttps:\/\/doi.org\/10.1111\/1346-8138.14273","journal-title":"J Dermatol"},{"issue":"5","key":"963_CR15","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/ccr3.911","volume":"5","author":"T Matsuo","year":"2017","unstructured":"Matsuo\u00a0T, Yamasaki\u00a0O (2017) Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD\u20111 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma. Clin Case Rep 5(5):694\u2013700. \nhttps:\/\/doi.org\/10.1002\/ccr3.911","journal-title":"Clin Case Rep"},{"issue":"8","key":"963_CR16","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/1346-8138.13612","volume":"44","author":"T Arai","year":"2017","unstructured":"Arai\u00a0T, Harada\u00a0K, Usui\u00a0Y, Irisawa\u00a0R, Tsuboi\u00a0R (2017) Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a\u00a0melanoma patient. J\u00a0Dermatol 44(8):975\u2013976. \nhttps:\/\/doi.org\/10.1111\/1346-8138.13612","journal-title":"J Dermatol"},{"issue":"3","key":"963_CR17","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.ajo.2003.08.035","volume":"137","author":"RE Andrade","year":"2004","unstructured":"Andrade\u00a0RE, Muccioli\u00a0C, Farah\u00a0ME, Nussenblatt\u00a0RB, Belfort\u00a0R Jr. (2004) Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 137(3):572\u2013574","journal-title":"Am J Ophthalmol"},{"key":"963_CR18","first-page":"41","volume":"3","author":"SM Couch","year":"2009","unstructured":"Couch\u00a0SM, Bakri\u00a0SJ (2009) Intravitreal triamcinolone for intraocular inflammation and associated macular edema. Clin Ophthalmol 3:41\u201347","journal-title":"Clin Ophthalmol"}],"updated-by":[{"DOI":"10.1007\/s00347-019-00987-5","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T00:00:00Z","timestamp":1571356800000}}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-019-00963-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-019-00963-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-019-00963-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T19:23:23Z","timestamp":1599161003000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-019-00963-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["963"],"URL":"https:\/\/doi.org\/10.1007\/s00347-019-00963-z","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,5]]},"assertion":[{"value":"5 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2019","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum zu:Der Ophthalmologe 2019<ExternalRef><RefSource>https:\/\/doi.org\/10.1007\/s00347-019-00963-z<\/RefSource><RefTarget Address=\"10.1007\/s00347-019-00963-z\" TargetType=\"DOI\"\/><\/ExternalRef>In dem urspr\u00fcnglichen Artikel wurde der Name der Autorin <Emphasis Type=\"Italic\">Nicole Eter<\/Emphasis> falsch geschrieben. Die Online-Version wurde korrigiert.Wir bitten, die korrigierte Schreibweise zu beachten und den Fehler zu \u2026","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"N.\u00a0Mihailovic, J.\u00a0Dyballa, S.\u00a0Herz, M.\u00a0Fluck, M.\u00a0Alnawaiseh, R.-L.\u00a0Mert\u00e9 und E.\u00a0Nicole geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}